# Phase II Study of Irinotecan and Panitumumab

> **NCT00836277** · PHASE2 · COMPLETED · sponsor: **Weijing Sun, MD, FACP** · enrollment: 24 (actual)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Panitumumab
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT00836277
- **Lead sponsor:** Weijing Sun, MD, FACP
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2016-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00836277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00836277, "Phase II Study of Irinotecan and Panitumumab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00836277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*